Abstract
Our group has been at the forefront of developing light scattering technologies (Nature 2000, Nat Med 2001, Gastro 2004, Clin Cancer Res 2006) and we have applied to cancer screening (reviewed in Gastro 2011). Our suite of technologies are sensitive to particle sizes from 50-500 nm thereby providing unprecedented insights into the nano-structural consequences of the genetic/epigenetic alterations in field carcinogenesis (Clin Cancer Res 2007, Gastro 2008, Cancer Res 2009). To maximize diagnostic performance, two critical issues need to be addressed, 1.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
